CARsgen Therapeutics’ Post

The preliminary results of Phase I of CT071 (#NCT05838131) were presented as a poster at the 29th #EHA Annual Congress on #June 14, 18:00 - 19:00 CEST, which was titled "First-in-human study of #GPRC5D-targeted #CAR T cells (CT071) with an accelerated manufacturing process in patients with relapsed/ refractory multiple #myeloma (RRMM)" https://lnkd.in/gGMHg-pV #Biotech #Celltherapy

📣 New publication alert!📣 We're delighted that our paper with innoVitro has been published: "Chamber-Specific Contractile Responses of Atrial and Ventricular hiPSC Cardiomyocytes to GPCR and Ion Channel Targeting Compounds: A Microphysiological System for Cardiac Drug Development". Human iPSC technology has been used to produce more human-relevant models for cardiac research and cardiotoxicity screening. But given the chamber-specific nature of certain conditions (for example, atrial fibrillation versus hypertrophic cardiomyopathy) these models must incorporate chamber types specific to the application. In collaboration with innoVitro, we sought to explore the chamber-specific pharmacology of axoCells™ atrial and ventricular cardiomyocytes on an innovative platform combining Nanion technologies' FLEXcyte 96 contractility platform with innoVitro's FLEXcyte plates. Our results demonstrated key pharmacological differences between axoCells atrial and ventricular cardiomyocytes and their application on a multi-well contractility platform to gain insights for in vitro cardiac liability studies and disease modelling. Click here to read the paper: https://hubs.la/Q02D8_z-0 #iPSCs #cardiomyocytes #CiPA #cardiotoxicity #StemCells

📣 New publication alert!📣 We're delighted that our paper with innoVitro has been published: "Chamber-Specific Contractile Responses of Atrial and Ventricular hiPSC Cardiomyocytes to GPCR and Ion Channel Targeting Compounds: A Microphysiological System for Cardiac Drug Development". Human iPSC technology has been used to produce more human-relevant models for cardiac research and cardiotoxicity screening. But given the chamber-specific nature of certain conditions (for example, atrial fibrillation versus hypertrophic cardiomyopathy) these models must incorporate chamber types specific to the application. In collaboration with innoVitro, we sought to explore the chamber-specific pharmacology of axoCells™ atrial and ventricular cardiomyocytes on an innovative platform combining Nanion technologies' FLEXcyte 96 contractility platform with innoVitro's FLEXcyte plates. Our results demonstrated key pharmacological differences between axoCells atrial and ventricular cardiomyocytes and their application on a multi-well contractility platform to gain insights for in vitro cardiac liability studies and disease modelling. Click here to read the paper: https://hubs.la/Q02D930Y0 #iPSCs #cardiomyocytes #CiPA #cardiotoxicity #StemCells

Click here for the full content: https://bit.ly/CT-759305 #IO23ASGCT Spotlight on Immuno-Oncology 2023 Analysis: #BRLMedicine reported clinical updates from BRL-201’s (#CD19 #Quikin CAR-T) Ph1 trial in r/r B-NHL patients, while #MeiraGTx and CERo Tx introduced their innovative technologies. Celltelligence provides insights and context for key selected presentations. The following topics are covered: • BRL Medicine presented updated clinical data from the Ph1 trial evaluating BRL-201 (CD19 Quikin CAR-T), the company’s novel CRISPR-based non-viral PD1 locus-specific integrated CD19 CAR-T, in r/r B-NHL patients • MeiraGTx presented its innovative riboswitch-regulated CAR-Ts (#RiboCAR inducible system) • #CERo Tx introduced its pioneering #CER (chimeric engulfment receptor) technology and highlighted the therapeutic potential of CER-1236 (PS CER-T) in #AML cells

Getting ready to share #IBA perspectives on the topic below!

Explore axoCells™ atrial and ventricular cardiomyocytes for robust, chamber-specific in vitro models. Here you can see our Senior Scientific Support Manager Steven Broadbent describe the results from a compound treatment assay we conducted in collaboration with innoVitro. We demonstrated that distinct pharmacological effects can be observed between axoCells atrial and ventricular cardiomyocytes when using the FLEXcyte 96 platform to assess contractility. Click here to access the full webinar recording of "Building chamber-specific cardiac models with iPSCs": https://hubs.la/Q02CtCsX0 If you'd like to read the full data set, click here for our application note: https://hubs.la/Q02CtBZ30 If you're working with iPSC-derived cardiomyocytes and would like to discuss how Axol Bioscience could help you to unlock the benefits of iPSC technology, get in touch at [email protected] #iPSCs #cardiotoxicity #CiPA #DrugDiscovery #AtrialFibrillation

More coverage of radiopharmaceuticals in Endpoints - they are really starting to talk about this space. Comparing Lu-177, Ac-225 and Pb-212: An under appreciated aspect of the therapeutic effect is the dose rate. Shorter half-lives typically mean higher administered activity is possible, leading to many more decays within the first 24 hrs. Approximately 80% of total alphas are emitted by Pb-212 within the first day, compared to 6% of total alphas from Ac-225 (ignoring the daughters of course). This means the molecule is very efficient, with peak radiation deposition at the time when the drug uptake in the tumor is also highest. I think this will be a key aspect that impacts the therapeutic window of these products significantly. #TAT #radiopharmaceuticals #theranostics https://lnkd.in/g5b8MS57

People talk about NFTs all the time, in fact they've reshaped much of our discourse here at #C2NDiagnostics. They have become so integral, that we developed a means to detect the presence and burden of these #NFTs. Check out some of the #groundbreaking work we have cooking up at #C2N! PS: I don't feel I need to clarify, but just in case, NFT obviously stands for "neurofibrillary tangle". 😁 #neuro #Alzheimers #neurology #NFT

More exciting news out of C2N Diagnostics #ctad23 #alzheimers #alzheimersdisease